Jane Street’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-70,516
| Closed | -$7.19M | – | 9658 |
|
|
2023
Q2 | $7.19M | Sell |
70,516
-8,527
| -11% | -$807K | ﹤0.01% | 2278 |
|
|
2023
Q1 | $7.19M | Buy |
79,043
+27,418
| +53% | +$1.61M | ﹤0.01% | 1988 |
|
|
2022
Q4 | $1.96M | Buy |
+51,625
| New | +$1.78M | ﹤0.01% | 3907 |
|
|
2022
Q3 | – | Sell |
-76,351
| Closed | -$2.12M | – | 10754 |
|
|
2022
Q2 | $2.32M | Buy |
76,351
+61,622
| +418% | +$1.84M | ﹤0.01% | 3881 |
|
|
2022
Q1 | $483K | Buy |
14,729
+707
| +5% | +$21K | ﹤0.01% | 7556 |
|
|
2021
Q4 | $370K | Buy |
14,022
+9,439
| +206% | +$730K | ﹤0.01% | 7790 |
|
|
2021
Q3 | $462K | Sell |
4,583
-478
| -9% | -$56K | ﹤0.01% | 7437 |
|
|
2021
Q2 | $716K | Sell |
5,061
-13,413
| -73% | -$1.51M | ﹤0.01% | 6542 |
|
|
2021
Q1 | $1.84M | Buy |
18,474
+5,400
| +41% | +$630K | ﹤0.01% | 4172 |
|
|
2020
Q4 | $1.62M | Sell |
13,074
-46,015
| -78% | -$6.05M | ﹤0.01% | 3887 |
|
|
2020
Q3 | $5.76M | Buy |
59,089
+7,543
| +15% | +$942K | ﹤0.01% | 1712 |
|
|
2020
Q2 | $8.04M | Buy |
51,546
+30,592
| +146% | +$4.65M | 0.01% | 1348 |
|
|
2020
Q1 | $3.02M | Buy |
20,954
+16,587
| +380% | +$3.2M | ﹤0.01% | 1617 |
|
|
2019
Q4 | $893K | Buy |
+4,367
| New | +$797K | ﹤0.01% | 2928 |
|
|
2019
Q2 | – | Sell |
-2,758
| Closed | -$236K | – | 5928 |
|
|
2019
Q1 | $236K | Buy |
+2,758
| New | +$229K | ﹤0.01% | 4502 |
|
Other funds holding RETA
Jane Street's RETA Position: Q3 2023 in Review
Jane Street sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 70,516 shares — an estimated $7.19M sold.
Jane Street first reported a position in RETA in Q1 2019 and held it in 15 quarters. The position peaked at $8.04M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Jane Street reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Jane Street sold 70,516 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $7.19M.
- Jane Street first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 15 quarters.
- Jane Street's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $8.04M in Q2 2020.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Jane Street's 13F filing for Q3 2023, filed 15 Nov 2023.